European regulators join their Canadian counterparts in starting a review of Novartis' (NVS)...

|About: Novartis AG (NVS)|By:, SA News Editor

European regulators join their Canadian counterparts in starting a review of Novartis' (NVS) hypertension pill aliskiren after a clinical trial indicated the drug may be linked to risks of nonfatal stroke and kidney problem. Earlier this week, Novartis stopped a large trial of aliskiren on the advice of an independent safety monitoring board.